Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCD-021 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Biocad
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
BCD-021 + carboplatin + paclitaxel is a drug combination studied for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). BCD-021 is a biosimilar of bevacizumab (Avastin). This combination has demonstrated therapeutic equivalence to the reference Avastin + carboplatin + paclitaxel regimen. Clinical trials have shown comparable objective response rates (ORR), complete response rates, partial response rates, and safety profiles. The administration sequence is critical, with paclitaxel typically given before carboplatin to maximize efficacy due to sequence-dependent interactions.
02
Targets
Beyond the preview
Go deeper on BCD-021 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCD-021 + carboplatin + paclitaxel.